Hematopoiesis News Volume 5.45 | Dec 2 2014

FGF Signaling Specifies Hematopoietic Stem Cells through Its Regulation of Somitic Notch Signaling
Researchers demonstrate a novel requirement for fibroblast growth factor (FGF) signaling in hematopoietic stem cell emergence. This requirement is non-cell-autonomous, and acts within the somite to bridge the Wnt and Notch signaling pathways. [Nat Commun] Abstract

Disruption of SF3B1 Results in Deregulated Expression and Splicing of Key Genes and Pathways in Myelodysplastic Syndrome Hematopoietic Stem and Progenitor Cells
Scientists investigated the functional effects of SF3B1 disruption in myeloid cell lines: SF3B1 knockdown resulted in growth inhibition, cell cycle arrest and impaired erythroid differentiation, and deregulation of many genes and pathways, including cell cycle regulation and RNA processing. [Leukemia] Abstract | Full Article

Constrained Transcription Factor Spacing Is Prevalent and Important for Transcriptional Control of Mouse Blood Cells
Utilizing a compendium of 289 mouse hematopoietic transcription factor ChIP-seq datasets, investigators demonstrate that hematopoietic-related motif-pairs commonly occur with highly conserved constrained spacing and orientation between motifs. [Nucleic Acids Res] Full Article

Abundance of the Fanconi Anemia Core Complex Is Regulated by the RuvBL1 and RuvBL2 AAA⁺ ATPases
Scientists show that the RuvBL1 and RuvBL2 adenosine triphosphatases associated with diverse cellular activities (AAA⁺ ATPases) co-purify with Fanconi anemia (FA) core complex isolated under stringent but native conditions from a vertebrate cell line. Depletion of the RuvBL1-RuvBL2 complex in human cells causes hallmark features of FA including DNA crosslinker sensitivity, chromosomal instability and defective FA pathway activation. [Nucleic Acids Res] Full Article

Wnt Signaling Is Involved in 6-Benzylthioinosine-Induced AML Cell Differentiation
Researchers investigated whether Wnt signaling pathways played roles in 6-benzylthioinosine-induced differentiation of acute myeloid leukemia (AML) cells. [BMC Cancer] Abstract | Full Article

CLINICAL RESEARCH

Comparative Therapeutic Value of Post Remission Approaches in Patients with Acute Myeloid Leukemia Aged 40-60 Years
Researchers report results of a time-dependent multivariable analysis of alloHSCT versus chemotherapy or autologous HSCT in 760 patients aged 40 and 60 years with acute myeloid leukemia in first complete remission. [Leukemia] Abstract

Pharmacogenetic Studies in Children with Acute Lymphoblastic Leukemia in Argentina
Investigators evaluated the influence of the most common genetic variants in methylenetetrahydrofolate reductase, thiopurine methyltransferase and glutathione-S-transferases on the outcome of acute lymphoblastic leukemia treatment in Argentinean children. [Leuk Lymphoma] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

CPRIT Awards UTSW Faculty $22.5 Million for Recruitment and Research in Liver Cancer, Leukemia, and Immunotherapy
UT Southwestern Medical Center faculty was awarded seven grants totaling more than $22 million from the Cancer Prevention and Research Institute of Texas (CPRIT) for investigations into leukemia, liver cancer, and immunotherapy, as well as to recruit new faculty. [UT Southwestern Medical Center] Press Release

Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Actinium Pharmaceuticals, Inc. announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. [Actinium Pharmaceuticals, Inc.] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

Mesenchymal Stem Cell (MSC) Laboratory Technician (California Cryobank)

Clinical Laboratory Scientist – Umbilical Cord Blood Processing (California Cryobank)

Head of Cellular and Molecular Therapies Laboratory (NHS Blood & Transplant)

Postdoctoral Researcher – Chromatin and Epigenetic Regulation (Van Andel Research Institute)

Postdoctoral Position – Post-Transcriptional Control of Gene Expression in Hematopoietic Stem Cells (Lund University)

Postdoctoral Fellow – Stem Cell Biology Gene Expression and Regulation (The University of Texas Medical School At Houston)

PhD Studentship – Discovery of Key Regulators of Normal and Leukemic Stem Cell Functions (University of Edinburgh)

Stem Cell Biology Program Director (Blood Research Institute of BloodCenter of Wisconsin)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.